Comparison of compliance and cost effectiveness between brand-name statins and generic statins
10.3760/cma.j.cn112338-20191114-00809
- VernacularTitle:原研他汀药及国产仿制他汀药的依从性及成本效果比较
- Author:
Liu HE
1
;
Xin DU
;
Wenhua WANG
;
Changsheng MA
Author Information
1. 首都医科大学附属北京安贞医院心内科，国家心血管疾病临床医学研究中心，北京市心血管疾病防治办公室，北京 100029
- Keywords:
Statins;
Brand-name drug;
Generic drug;
Compliancy;
Cost effectiveness
- From:
Chinese Journal of Epidemiology
2020;41(11):1900-1904
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the differences of adherence, lipid reduction and cost-effectiveness between brand-name and generic statins.Methods:Statins prescription records of adult patients aged 18 years and above with the first prescription of statins between January 2015 to December 2017, were collected from community health information system of Chaoyang district of Beijing. Medication compliancy after first prescription was compared between group only taking brand-name statins (41 496 records) and group only taking generic statins (60 491 records). Lipid reduction and cost-effectiveness were also compared between two groups.Results:The medication compliancy of generic statins was worse than brand-name statins (28.2 % vs. 36.2 %, P<0.001). After excluding the influence of age, sex, history of hypertension and diabetes, and community correlation, generic atorvastatin (20 mg/day) showed better total cholesterol reduction effect [(0.86±0.07) mmol/L] and better low density lipid-cholesterol reduction effect [(0.67±0.07) mmol/L] one year later in 199 patients who consistently used it compared with brand-name atorvastatin at same dosage in 232 patients [(0.40±0.10) mmol/L and (0.42±0.08) mmol/L] ( P<0.001, P=0.003). From the perspective of cost effectiveness, generic atorvastatin (20 mg/day) can reduce more than 50 % of medical expenses at the same cholesterol reduction level. Conclusions:Generic statins might replace brand-name statins with similar treatment effect but lower medical expenses although its compliancy needs improvement. However, the data of adverse reactions of generic statins are lacking, it is necessary to carry out high-quality clinical research to improve and promote the development of generic statins.
